Three-dimensional (3D) printing represents a pivotal technological advancement in dental prosthetics, fundamentally transforming the fabrication of provisional crowns and bridges through innovative vat photopolymerization methodologies, specifically stereolithography (SLA) and digital light processing (DLP). This comprehensive scholarly review critically examines the technological landscape of 3D-printed resin-based dental provisional crowns and bridges, systematically analyzing their material performance, clinical applications, and prospective developmental trajectories. Empirical investigations demonstrate that these advanced restorations exhibit remarkable mechanical characteristics, including flexural strength ranging from 60 to 90 MPa and fracture resistance of 1000–1200 N, consistently matching or surpassing traditional manufacturing techniques. The digital workflow introduces substantial procedural innovations, dramatically reducing fabrication time while simultaneously achieving superior marginal adaptation and internal architectural precision. Despite these significant technological advancements, critical challenges persist, encompassing material durability limitations, interlayer bonding strength inconsistencies, and the current paucity of longitudinal clinical evidence. Contemporary research initiatives are strategically focused on optimizing resin formulations through strategic filler incorporation, enhancing post-processing protocols, and addressing fundamental limitations in color stability and water sorption characteristics. Ultimately, this scholarly review aims to provide comprehensive insights that will inform evidence-based clinical practices and delineate future research trajectories in the dynamically evolving domain of digital dentistry, with the paramount objective of advancing patient outcomes through technological innovation and precision-driven methodological approaches.

Background/Objectives: Hepatocellular carcinoma (LIHC) poses significant challenges due to limited targeted therapeutic options. This study investigates SMYD5, an oncogene implicated in the pathogenesis of LIHC, and its interaction with the BRD4 protein. Methods: We employed bioinformatics analyses alongside experimental validations to assess SMYD5 expression across various cancers, particularly LIHC. This included survival analysis, protein expression studies, and functional assays to understand the role of SMYD5 in LIHC progression. Results: Our findings demonstrate that SMYD5 expression is markedly elevated in LIHC tumor tissues compared to normal liver tissues. Moreover, high levels of SMYD5 correlate with poor overall survival and disease-free survival rates in LIHC patients. Functional assays indicate that the knockdown of SMYD5 significantly inhibits cell proliferation and increases apoptosis in LIHC cell lines. Additionally, a notable interaction between SMYD5 and BRD4 was identified, suggesting a potential therapeutic target in the SMYD5-BRD4 axis. Conclusions: These findings collectively establish SMYD5 as a molecular driver in LIHC pathology and identify the SMYD5-BRD4 interaction axis as a promising therapeutic target for future drug development.